First-generation H1 antagonist with anxiolytic + sedating + antiemetic activity. Common alternative to benzodiazepines for anxiety due to no addiction potential. Anticholinergic burden — Beers-list problematic. Cetirizine is the active metabolite.
Half-Life & Elimination Curve (PO: 3h)
Plasma (PO)t½ Decay (3h)Effect Site (ke0)
0×t½0h100%(22 µg/L)
1×t½3h50%(11 µg/L)
2×t½6h25%(5.5 µg/L)
3×t½9h12.5%(2.75 µg/L)
4×t½12h6.3%(1.38 µg/L)
5×t½15h3.1%(0.688 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)1.22h
Est. Peak (Cmax)22 µg/L
Clearance (CL)277 L/h
97% Washout (5×t½)15h
Dosing Guidelines
Oral (PO): Typical 50 mg (Range: 25–100 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 70% · Volume of Distribution (Vd): 1200 L · Absorption (ka): 2 h⁻¹ (t½ka ≈ 21m) [PMID 512901]